A Phase III, Randomised, Multicenter, Double-blind, Parallel-group, Active Controlled Study to Evaluate the Efficacy and Safety of Oral Dabigatran Etexilate (150 mg Bid) Compared to Warfarin (INR 2.0-3.0) for the Secondary Prevention of Venous Thromboembolism.
A Phase III, Randomised, Multicenter, Double-blind, Parallel-group, Active Controlled Study to Evaluate the Efficacy and Safety of Oral Dabigatran Etexilate (150 mg Bid) Compared to Warfarin (INR 2.0-3.0) for the Secondary Prevention of Venous Thromboembolism.
The general aim of this study is to determine the comparative safety and efficacy of dabigatran etexilate administered orally and warfarin (International Normalized Ratio (INR) of 2.0-3.0) for the long-term treatment and secondary prevention of symptomatic venous thromboembolism in patients who have been successfully treated with standard doses of an approved anticoagulant for three to twelve months for confirmed acute symptomatic Venous Thrombo-embolism.
Inclusion criteria:
Inclusion_Criteria
Exclusion criteria:
Exclusion_Criteria
Roxbury Crossing, Massachusetts, United States
Capital Federal, Argentina
Capital Federal, Argentina
Capital Federal, Argentina
Capital Federal, Argentina
Capital Federal, Argentina
Capital Federal, Argentina
Wooloongabba, Queensland, Australia
Campinas - SP, Brazil
Juvene - Paraná -, Brazil
pTO aLEGRE, Brazil
Rio de Janeiro - RJ, Brazil
Saint Johns, New Brunswick, Canada
Ostrava-Vitkovice, Czechia
Guadalajara, Jal., Mexico
Takapuna Auckland 9, New Zealand
Cartagena. Murcia, Spain
Headington, Oxford, United Kingdom